Company / PP&E (Net)
Fulcrum Therapeutics, Inc. PP&E (Net) History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$2.8M
FY2025
5-year range
$2.8M / $7.4M
FY2021-FY2025
Trend
-27.6%
vs FY2024
Sector context
#124 of 193
Health Care
What the data says
At $3M, Fulcrum Therapeutics, Inc.'s pp&e (net) ranks #124 of 193 in the Health Care sector. PP&E (Net) has declined for 7 consecutive years, from $11M in FY2018 to $3M in FY2025.
Based on SEC 10-K filings.
$3M in FY2025 with a 5-year CAGR of -19.6%.
Declined from $5M to $3M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -25.8%
- 5-Year CAGR
- -19.6%
- 10-Year CAGR
- -
Sector benchmark
#124 of 193 in Health CareTop 64% of 193This company $2.8M Sector average $777.6M
▼
-99.6% below sector average
Key checks
Key Insights
- Fulcrum Therapeutics, Inc.'s pp&e (net) has declined for 7 consecutive years.
- 5-year CAGR of -19.6%, indicating a declining trend.
- In FY2025, pp&e (net) decreased 27.6% year-over-year.
- Ranks #124 out of 193 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 8.44 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.8M | -27.6% |
| FY2024 | $3.9M | -25.2% |
| FY2023 | $5.2M | -24.5% |
| FY2022 | $6.9M | -6.3% |
| FY2021 | $7.4M | -12.3% |
| FY2020 | $8.4M | -8.8% |
| FY2019 | $9.2M | -12.7% |
| FY2018 | $10.5M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026